Navigating the Operational Challenges of Treatment with Bispecific Antibodies - [Podcast] Ep 148

CANCER BUZZ speaks with Aaron Cumpston, PharmD, and Christine Barrett, PharmD, BCOP, who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community setting.

Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!

Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at WVU Cancer Institute who discusses the challenges of care coordination and therapy and shares operational best practices for the delivery of bispecific antibodies in the community setting.

“I think we’re finding these drugs [bispecific T-cell engagers (BiTE) therapies] to be highly effective and having high response rates and also very durable response rates in very refractory patients.”—Aaron Cumpston, PharmD, BCOP

“I know that in community practice it can be really difficult, but there is a network of institutions out there that have taken on administering these BiTE therapies and have a lot of experience that can be very helpful for those in community practice.” —Christine Barrett, PharmD, BCOP

Guests: